Brazilian pharmaceutical company EMS received authorization from Anvisa for the national production of liraglutide, an active ingredient present in medicines such as Ozempic, famous for its effects on weight loss and control of type 2 diabetes. The information was found by the newspaper Folha de São Paulo.
With the approval, EMS enters the competition for a booming market, which already has names like Saxenda and Mounjaro. The company invested more than R$150 million in the factory in Hortolândia (SP), which will be responsible for the development and production of the medicine.
Read more:
The entry of EMS into the national market promises to expand access to this type of medicine, which currently depends on imports and suffers from frequent supply problems. EMS’s new medicines will be marketed under the brand names Olire, for obesity, and Lirux, for type 2 diabetes.
With the authorization given to EMS, the Brazilian pharmaceutical industry achieved the first global production record of a synthetic polypeptide.
